PROCEPT BioRobotics Corporation Announces Pricing of Upsized Initial Public Offering
15 9월 2021 - 8:03AM
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (“PROCEPT”), a
commercial-stage surgical robotics company focused on advancing
patient care by developing transformative solutions in urology,
today announced the pricing of its upsized initial public offering
of 6,556,000 shares of its common stock at a public offering price
of $25.00 per share, for total gross proceeds of $163.9 million,
before deducting underwriting discounts and commissions and
estimated offering expenses. All of the shares are being offered
and sold by PROCEPT. PROCEPT’s common stock is expected to begin
trading on the Nasdaq Global Market on September 15, 2021, under
the ticker symbol "PRCT." The offering is expected to close on
September 17, 2021, subject to the satisfaction of customary
closing conditions. In addition, PROCEPT has granted the
underwriters a 30-day option to purchase up to an additional
983,400 shares of common stock at the initial public offering
price, less the underwriting discounts and commissions.
BofA Securities and Goldman Sachs & Co. LLC are acting as
joint lead bookrunning managers for the offering. Cowen, Guggenheim
Securities and SVB Leerink are acting as co-managers.
Registration statements relating to the offering have been filed
with the Securities and Exchange Commission and became effective on
September 14, 2021. The offering is being made only by means of a
prospectus, copies of which may be obtained from: BofA Securities,
NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC
28255-0001, Attention: Prospectus Department, or by email at
dg.prospectus_requests@bofa.com; or Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY
10282, by telephone at (866) 471-2526, or by email
at Prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or jurisdiction.
About PROCEPT BioRobotics Corporation
PROCEPT is a commercial-stage surgical robotics company focused
on advancing patient care by developing transformative solutions in
urology. PROCEPT develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally-invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT designed Aquablation therapy to
deliver effective, safe and durable outcomes for males suffering
from lower urinary tract symptoms, or LUTS, due to BPH that are
independent of prostate size and shape or surgeon experience.
PROCEPT has developed a significant and growing body of clinical
evidence, which includes nine clinical studies and over 100
peer-reviewed publications, supporting the benefits and clinical
advantages of Aquablation therapy.
Forward Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “may,”
“will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negative of
these terms or other similar expressions, and include, without
limitation, statements regarding PROCEPT’s expectations regarding
the commencement of trading of its shares on the Nasdaq Global
Market, the size, completion and timing of the closing of the
offering. Forward-looking statements are based on PROCEPT’s current
expectations and assumptions and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Important factors that could cause actual results to differ
include, but are not limited to, risks and uncertainties related to
the satisfaction of customary closing conditions related to, and
the completion of, the initial public offering. These and other
risks and uncertainties are described more fully in the section
titled “Risk Factors” in the prospectus related to the initial
public offering to be filed with the U.S. Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made only as of the date of this release, and
PROCEPT undertakes no obligation to update such information except
as required under applicable law.
Investor Contact:Gilmartin GroupMatt Bacso,
CFAMatt.bacso@gilmartinir.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024